EYEN - יחס חוב להיוון בספרים eyenovia.com

When monitoring leverage relative to equity on GURU.Markets, it is evident that 0.00 expresses the metric's value today for Eyenovia, Inc. (EYEN). Current revenue is generated by the sale of the Optejet system, although potential FDA delays and the need for secondary offerings raise concerns. Furthermore, medical insurance complexities and a narrow market niche continue to constrain growth.

Investors assess fundamental threats to capital by analyzing debt load. For Eyenovia, Inc. (EYEN), which delegates production and testing to external partners, financial stability is critical. The historical debt-to-book capitalization ratio compares total liabilities to equity. An increase in this indicator signals a dangerous rise in leverage, while a low value confirms the company's ability to develop therapy without excessive credit pressure.